CANY
MRNA icon

Caxton Associates (New York)’s Moderna MRNA Stock Holding History

Caxton Associates (New York)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,600
Closed -$399K – 600
2023
Q1 		$399K Sell
2,600
-236,860
-99% -$39.1M 0.06% 302
2022
Q4 		$43M Buy
239,460
+700
+0.3% +$114K 2.87% 6
2022
Q3 		$28.2M Buy
238,760
+2,601
+1% +$395K 3.76% 4
2022
Q2 		$33.7M Buy
236,159
+67,399
+40% +$9.63M 3.28% 6
2022
Q1 		$29.1M Buy
168,760
+104,600
+163% +$17.6M 2.37% 7
2021
Q4 		$16.3M Sell
64,160
-581
-0.9% -$170K 1.66% 13
2021
Q3 		$24.9M Buy
64,741
+61,320
+1,792% +$22.6M 2.75% 5
2021
Q2 		$804K Sell
3,421
-854
-20% -$153K 0.09% 99
2021
Q1 		$560K Buy
+4,275
New +$619K 0.05% 144

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caxton Associates (New York)'s MRNA Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Moderna (MRNA) in Q2 2023, closing a stake of 2,600 shares — an estimated $399K sold.

Caxton Associates (New York) first reported a position in MRNA in Q1 2021 and held it in 9 quarters. The position peaked at $43M in Q4 2022. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 2,600 Moderna shares in Q2 2023, an estimated $399K.
  • Caxton Associates (New York) first reported a position in Moderna in Q1 2021 and held it in 9 quarters.
  • Caxton Associates (New York)'s Moderna position peaked at $43M in Q4 2022.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.